Cargando…

Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review

Detalles Bibliográficos
Autores principales:	Ma, Julie, Morimoto, Kenji, Pulsipher, Michael A., Parekh, Chintan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309544/ https://www.ncbi.nlm.nih.gov/pubmed/37315262 http://dx.doi.org/10.1200/PO.22.00693

Ejemplares similares

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Mutated Fanconi anemia pathway in non-Fanconi anemia cancers
por: Shen, Yihang, et al.
Publicado: (2015)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia
por: Fujino, Keita, et al.
Publicado: (2023)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
por: Naka, Ryosuke, et al.
Publicado: (2023)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
por: Bankur, Mustafa Nissar, et al.
Publicado: (2022)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
por: Liu, Kaiqi, et al.
Publicado: (2021)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine
por: Zhang, Alexander, et al.
Publicado: (2022)

A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia
por: Hu, Rong-Hua, et al.
Publicado: (2022)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
por: Sofía, Álvarez-Galeano, et al.
Publicado: (2023)

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Mutations of the SLX4 gene in Fanconi anemia
por: Kim, Yonghwan, et al.
Publicado: (2011)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report
por: Kim, Mihee, et al.
Publicado: (2021)

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
por: Ong, Shin Yeu, et al.
Publicado: (2022)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

P518: VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS
por: LI, Zheng, et al.
Publicado: (2023)

Treatment of Fanconi anemia patients using fludarabine and low-dose total body irradiation followed by unrelated donor hematopoietic cell transplantation
por: Thakar, Monica S, et al.
Publicado: (2010)

Successful Treatment of Fanconi Anemia and T-Cell Acute Lymphoblastic Leukemia
por: Flatt, Terrie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_se6hi6pojb625fdj86ckmm6t7h